Polydextrose for Patients With Chronic Kidney Disease

Effects of Polydextrose Supplementation on Constipation in Patients Undergoing Hemodialysis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05336305

Enrollment

Registered

2022-04-20

Start date

2021-03-30

Completion date

2021-10-30

Last updated

2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, Constipation

Brief summary

Constipation is a common complication in patients with chronic kidney disease (CKD), especially in hemodialysis (HD) patients. Reduced intake of fibre-rich food is among the most important causes of constipation. The study aims to investigate the possible influence of polydextrose (PDX) supplementation on constipation in patients with CKD on HD.

Interventions

DIETARY_SUPPLEMENTPolydextrose

Administration of 3g polydextrose per day, for 2 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of Chronic Kidney Disease * Hemodialysis patients for more than 6 months * Aged 18 years or older

Exclusion criteria

* Patients pregnant * Smokers * Using antibiotics in the last 3 months * Autoimmune diseases * Clinical diagnosis of infectious diseases * Clinical diagnosis of Cancer * Clinical diagnosis of AIDS

Design outcomes

Primary

Measure	Time frame	Description
Change constipation status after supplementation with polydextrose	2 months	Stool frequency and Bristol Stool Form
Change in cytokines plasma levels measured by ELISA after supplementation with polydextrose	2 months	cytokines levels

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026